GSK, Verona, Italy.
Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
J Matern Fetal Neonatal Med. 2021 Jul;34(13):2132-2139. doi: 10.1080/14767058.2019.1659240. Epub 2019 Sep 4.
Pertussis is a widespread vaccine-preventable disease, associated with an increasing trend to hospitalization among newborns. Pertussis in newborns can be fatal, and the most effective way to prevent it is maternal immunization (MI) with a reduced antigen content tetanus, diphtheria, and acellular pertussis vaccine (Tdap). In Italy, the National Immunization Plan (NIP) 2017-2019 introduced Tdap vaccination during each pregnancy at no cost for the recipient. Despite this, vaccination coverage is suboptimal. This survey of pregnant women across Italy was conducted to investigate their knowledge and expectations of Tdap.
A cross-sectional survey was conducted. Pregnant women up to 28th gestational weeks were interviewed by Telephone using a questionnaire with 16 questions. Statistics were descriptive.
The final sample recruited 600 respondents evenly distributed across Italy. The average duration of pregnancy at the time of the interview was 20.8 weeks (standard deviation [SD] 6.0). Most women (60.7%) were between 30 and 40 years of age. About half were aware of the risks of pertussis for newborns (54.5%) and the increased risk of hospitalization (59.8%); 47.2% were aware that Tdap MI was offered free of charge under the NIP. Safety information regarding the mother and newborn was considered the most important information in deciding whether to be vaccinated (47.4%), followed by safety information related only to the newborn (29.5%). About half (52.2%) stated that they would "certainly" accept MI, and 25.3% would like to receive more information. Gynecologists were the preferred healthcare providers (HCPs) for the provision of MI information (34.3%), followed by pediatricians (25.5%). Two-thirds of the respondents would prefer to be informed about MI before getting pregnant (66.0%). Vaccines investigated specifically for use in pregnancy were preferred by respondents. Overall, no relevant differences were observed between women pregnant for the first time and those with more than one pregnancy, nor between geographical regions.
The results show room for improving the awareness and understanding of the risks of pertussis for infants and the protective role of MI. The pregnant women preferred to receive advice on MI from an HCP, primarily their gynecologist. They were most interested in information on the safety profile of Tdap during pregnancy, on the mother, fetus, and newborn. The potential impact of this study to support clinical practice of Healthcare Providers is highlighted in the Focus on the Patient section. [Formula: see text].
百日咳是一种广泛存在的可通过疫苗预防的疾病,与新生儿住院率的上升趋势有关。新生儿患百日咳可能致命,预防该病最有效的方法是孕妇接种含低抗原含量的破伤风、白喉和无细胞百日咳疫苗(Tdap)。在意大利,2017-2019 年国家免疫计划(NIP)为每位孕妇在怀孕期间免费接种 Tdap。尽管如此,疫苗接种覆盖率仍不理想。本研究对意大利各地的孕妇进行了调查,以了解她们对 Tdap 的认识和期望。
采用横断面调查。通过电话对妊娠 28 周以内的孕妇进行问卷调查,共 16 个问题。统计学分析采用描述性分析。
最终共招募了 600 名受访者,在意大利各地均匀分布。访谈时的平均妊娠周数为 20.8 周(标准差[SD] 6.0)。大多数孕妇(60.7%)年龄在 30-40 岁之间。约一半的孕妇知晓百日咳对新生儿的风险(54.5%)和住院风险增加(59.8%);47.2%的孕妇知晓 NIP 下免费提供 Tdap 疫苗接种。在决定是否接种疫苗时,母亲和新生儿的安全性信息被认为是最重要的信息(47.4%),其次是仅与新生儿相关的安全性信息(29.5%)。约一半(52.2%)的孕妇表示肯定会接受 MI,25.3%的孕妇希望获得更多信息。妇产科医生是提供 MI 信息的首选医护人员(34.3%),其次是儿科医生(25.5%)。三分之二的受访者希望在怀孕前获得关于 MI 的信息(66.0%)。受访者更喜欢专门用于妊娠的疫苗。总的来说,首次妊娠的孕妇和多次妊娠的孕妇、不同地理区域的孕妇之间没有观察到显著差异。
结果表明,提高孕妇对婴儿百日咳风险的认识和理解以及 MI 的保护作用仍有改进空间。孕妇更愿意从医护人员那里获得关于 MI 的建议,主要是从妇产科医生那里获得建议。她们最感兴趣的是 Tdap 在怀孕期间、母亲、胎儿和新生儿的安全性概况信息。本研究可能会支持医护人员的临床实践,在重点关注患者部分进行了强调。